The CD52 molecule (Cambridge pathology 1 antigen, CAMPATH-1 antigen) [115]–[123] is targeted by Alemtuzumab and there are recent reports that indicate that it may be an effective treatment for early MS [124]. The gene discussed is CD52; the disease is myeloid sarcoma.